NeuroPace appreciates CMS's decision to maintain current MS-DRG assignment for its RNS System, supporting epilepsy patients' access.
Quiver AI Summary
NeuroPace, Inc. announced that the Centers for Medicare & Medicaid Services (CMS) has chosen not to finalize its proposed reassignment of epilepsy treatment cases involving neurostimulator devices for the FY 2026 Inpatient Prospective Payment System. NeuroPace's CEO, Joel Becker, expressed appreciation for CMS's engagement with public comments and supported the decision to keep the current assignment for the RNS® System procedures, which is crucial for the hospitals serving Medicare beneficiaries with epilepsy. The company remains committed to collaborating with CMS on improving Medicare reimbursement policies to enhance access to the RNS System for patients with drug-resistant epilepsy and other brain disorders.
Potential Positives
- NeuroPace successfully influenced CMS to maintain the current MS-DRG assignment for its RNS® System procedures, ensuring continuity for hospitals serving Medicare beneficiaries.
- The decision by CMS supports access to innovative treatment for vulnerable epilepsy patients, reinforcing NeuroPace's commitment to improving patient care.
- NeuroPace’s RNS System is highlighted as a unique and advanced solution for drug-resistant epilepsy, showcasing the company’s leadership in clinical innovation within the medical technology space.
Potential Negatives
- The CMS decision not to finalize the proposed reassignment may limit future reimbursement opportunities for NeuroPace's RNS System, potentially affecting their market growth.
- The statement reflects ongoing uncertainty regarding reimbursement policies, which could impact investor confidence and the company's financial stability.
- The reliance on public comment and collaboration with CMS indicates a lack of control over regulatory outcomes, highlighting the vulnerabilities the company faces in navigating the healthcare reimbursement landscape.
FAQ
What is the main focus of NeuroPace, Inc.?
NeuroPace focuses on transforming the lives of individuals living with epilepsy through innovative medical technology.
What decision did CMS make regarding RNS System procedures?
CMS decided to maintain the current MS-DRG assignment for RNS System procedures under MS-DRG 023.
How does the RNS System benefit patients?
The RNS System provides personalized, real-time treatment at the seizure source, aiming to reduce or eliminate debilitating seizures.
What is NeuroPace's commitment to CMS?
NeuroPace is committed to working with CMS on MS-DRG improvements and ensuring access to the RNS System for those in need.
What should investors know about NeuroPace's forward-looking statements?
Investors should be cautious as forward-looking statements may not accurately predict future events or outcomes for NeuroPace.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$NPCE Insider Trading Activity
$NPCE insiders have traded $NPCE stock on the open market 4 times in the past 6 months. Of those trades, 0 have been purchases and 4 have been sales.
Here’s a breakdown of recent trading of $NPCE stock by insiders over the last 6 months:
- LTD. KCK sold 5,270,845 shares for an estimated $49,545,943
- ADVISORS LLC ORBIMED has made 0 purchases and 2 sales selling 168,136 shares for an estimated $2,665,332.
- MARTHA MORRELL (CHIEF MEDICAL OFFICER) sold 78,334 shares for an estimated $1,074,844
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$NPCE Hedge Fund Activity
We have seen 58 institutional investors add shares of $NPCE stock to their portfolio, and 24 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- KCK LTD. removed 5,270,845 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $64,778,685
- POLAR CAPITAL HOLDINGS PLC added 2,972,003 shares (+inf%) to their portfolio in Q1 2025, for an estimated $36,525,916
- FIRST LIGHT ASSET MANAGEMENT, LLC added 1,584,048 shares (+inf%) to their portfolio in Q1 2025, for an estimated $19,467,949
- DRIEHAUS CAPITAL MANAGEMENT LLC added 803,440 shares (+inf%) to their portfolio in Q1 2025, for an estimated $9,874,277
- ARMISTICE CAPITAL, LLC added 561,000 shares (+94.7%) to their portfolio in Q1 2025, for an estimated $6,894,689
- KENT LAKE PR LLC removed 532,555 shares (-35.9%) from their portfolio in Q1 2025, for an estimated $6,545,100
- DEUTSCHE BANK AG\ added 511,662 shares (+124.0%) to their portfolio in Q1 2025, for an estimated $6,288,325
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$NPCE Analyst Ratings
Wall Street analysts have issued reports on $NPCE in the last several months. We have seen 3 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 05/28/2025
- JP Morgan issued a "Overweight" rating on 05/14/2025
- Cantor Fitzgerald issued a "Overweight" rating on 05/14/2025
To track analyst ratings and price targets for $NPCE, check out Quiver Quantitative's $NPCE forecast page.
$NPCE Price Targets
Multiple analysts have issued price targets for $NPCE recently. We have seen 3 analysts offer price targets for $NPCE in the last 6 months, with a median target of $17.0.
Here are some recent targets:
- Yi Chen from HC Wainwright & Co. set a target price of $18.0 on 05/28/2025
- Robbie Marcus from JP Morgan set a target price of $16.0 on 05/14/2025
- Ross Osborn from Cantor Fitzgerald set a target price of $17.0 on 05/14/2025
Full Release
MOUNTAIN VIEW, Calif., Aug. 01, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical technology company focused on transforming the lives of people living with epilepsy, today issued the following statement in response to the Centers for Medicare & Medicaid Services (CMS) electing not to finalize its proposed reassignment of epilepsy with neurostimulator cases in the FY 2026 Inpatient Prospective Payment System (IPPS) rule.
“We appreciate CMS’ openness to public comment on the proposed rule and its reconsideration of the original proposal to reassign RNS cases to MS-DRG 020-022. We commend CMS’ decision to maintain the current MS-DRG assignment for RNS® System procedures under MS-DRG 023,” said Joel Becker, Chief Executive Officer of NeuroPace. “This maintains continuity for hospitals providing the RNS System to Medicare beneficiaries, who represent a vulnerable and underserved epilepsy population.”
NeuroPace will continue to work with CMS on MS-DRG improvements and other reimbursement related topics. The company remains committed to ensuring that reimbursement policy keeps pace with clinical innovation and that access to the RNS System is available for all who may benefit.
About NeuroPace, Inc.
Based in Mountain View, Calif., NeuroPace is a medical device company focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of debilitating seizures. Its novel and differentiated RNS System is the first and only commercially available, brain-responsive platform that delivers personalized, real-time treatment at the seizure source. This platform can drive a better standard of care for patients living with drug-resistant epilepsy and has the potential to offer a more personalized solution and improved outcomes to the large population of patients suffering from other brain disorders.
Forward Looking Statements
This press release may contain forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will” and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. NeuroPace may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements.
Forward-looking statements in this press release include, but are not limited to, statements regarding: the outcomes of NeuroPace’s continued work with CMS on Medicare reimbursement for the RNS System.
Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various factors, including: risks related to the pricing of the RNS System and availability of adequate reimbursement for the procedures to implant the RNS System and for clinicians to provide ongoing care for patients treated with the RNS System
. These and other risks and uncertainties include those described more fully in the section titled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere in NeuroPace’s public filings with the U.S. Securities and Exchange Commission (SEC), including its Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, filed with the SEC on May 13, 2025, as well as any other reports that it may file with the SEC in the future. Forward-looking statements contained in this announcement are based on information available to NeuroPace as of the date hereof. NeuroPace undertakes no obligation to update such information except as required under applicable law. These forward-looking statements should not be relied upon as representing NeuroPace’s views as of any date subsequent to the date of this press release and should not be relied upon as a prediction of future events. In light of the foregoing, investors are urged not to rely on any forward-looking statement in reaching any conclusion or making any investment decision about any securities of NeuroPace.
Investor Contact:
Scott Schaper
Head of Investor Relations
[email protected]
[email protected]